Nally Michael 4

What Happened

• Michael Nally, CEO of Generate Biomedicines (GENB), was reported to have received two grants of derivative securities on Feb 26, 2026 (844,595 shares each) and, upon the company’s IPO, converted derivative securities on Mar 2, 2026. The Form 4 shows: two awards of 844,595 derivative shares (acquired at $0.00) on 2026-02-26; on 2026-03-02 a conversion resulting in acquisition of 658,327 shares and a conversion/disposition of 1,000,000 derivative shares (reported at $0.00).
• These entries reflect awards and an IPO-driven conversion of derivative securities rather than an open-market buy or sale; there is no cash purchase or sale value reported in the filing.

Key Details

• Transaction dates: Grants/awards recorded 2026-02-26; conversion(s) recorded 2026-03-02; Form 4 filed 2026-03-02.
• Prices/values: Grants reported at $0.00 (derivative awards). Conversion/disposition entries reported at $0.00 or N/A; no cash proceeds or market-sale amounts reported.
• Shares reported in filing: two grants of 844,595 each (total 1,689,190 granted); conversion entries show acquisition of 658,327 shares and disposition of 1,000,000 derivative shares.
• Post-transaction beneficial ownership: Not specified in the provided excerpt of the filing.
• Footnotes of note:
  • F1: Each Series A Preferred automatically converted into common on a 1-for-1.5190 basis upon the IPO closing on March 2, 2026 (this explains the conversions tied to the IPO).
  • F2: Reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
  • F3/F4: Vesting schedules apply to underlying awards (one set vests in two installments in 2029–2030; another vests monthly over 48 months beginning Feb 19, 2026).
• Timeliness: Filing date is Mar 2, 2026 for transactions on Feb 26 and Mar 2; the Form 4 shows these events were reported on Mar 2. (No explicit late-filing flag was provided in the excerpt.)

Context

• These entries look like routine IPO-related conversions (preferred → common) and the grant of derivative instruments subject to vesting, not an open-market purchase or a sale for cash. Conversions tied to an IPO are typically mechanical (per F1) and do not necessarily signal a change in insider sentiment.
• Because the filing includes derivative awards and a conversion, note that vesting schedules and any disclaimers of beneficial ownership (F2) affect how much of the common stock the CEO actually controls today.